BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents. 2017

Tooba Abdizadeh, and Mohammad Reza Kalani, and Khalil Abnous, and Zahra Tayarani-Najaran, and Bibi Zahra Khashyarmanesh, and Rahman Abdizadeh, and Razieh Ghodsi, and Farzin Hadizadeh
Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

Histone deacetylases (HDACs) are attractive therapeutic targets for the treatment of cancer and other diseases. It has four classes (I-IV), among them especially class I isozyme are involved in promoting tumor cells proliferation, angiogenesis, differentiation, invasion and metastasis and also viable targets for cancer therapeutics. A novel series of coumarin-based benzamides was designed and synthesized as HDAC inhibitors. The cytotoxic activity of the synthesized compounds (8a-u) was evaluated against six human cancer cell lines including HCT116, A2780, MCF7, PC3, HL60 and A549 and a single normal cell line (Huvec). We evaluated their inhibitory activities against pan HDAC and HDAC1 isoform. Four compounds (8f, 8q, 8r and 8u) showed significant cytotoxicity with IC50 in the range of 0.53-57.59 μM on cancer cells and potent pan-HDAC inhibitory activity (consists of HDAC isoenzymes) (IC50 = 0.80-14.81 μM) and HDAC1 inhibitory activity (IC50 = 0.47-0.87 μM and also, had no effect on Huvec (human normal cell line) viability (IC50 > 100 μM). Among them, 8u displayed a higher potency for HDAC1 inhibition with IC50 value of 0.47 ± 0.02 μM near equal to the reference drug Entinostat (IC50 = 0.41 ± 0.06 μM). Molecular docking studies and Molecular dynamics simulation of compound 8a displayed possible mode of interaction between this compound and HDAC1enzyme.

UI MeSH Term Description Entries
D003374 Coumarins Synthetic or naturally occurring substances related to coumarin, the delta-lactone of coumarinic acid. 1,2-Benzopyrone Derivatives,1,2-Benzopyrones,Coumarin Derivative,Coumarine,1,2-Benzo-Pyrones,Benzopyran-2-ones,Coumarin Derivatives,Coumarines,1,2 Benzo Pyrones,1,2 Benzopyrone Derivatives,1,2 Benzopyrones,Benzopyran 2 ones,Derivative, Coumarin,Derivatives, 1,2-Benzopyrone,Derivatives, Coumarin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001549 Benzamides BENZOIC ACID amides.
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D056004 Molecular Dynamics Simulation A computer simulation developed to study the motion of molecules over a period of time. Molecular Dynamics Simulations,Molecular Dynamics,Dynamic, Molecular,Dynamics Simulation, Molecular,Dynamics Simulations, Molecular,Dynamics, Molecular,Molecular Dynamic,Simulation, Molecular Dynamics,Simulations, Molecular Dynamics
D056284 Histone Deacetylase 1 A histone deacetylase subtype that is found along with HISTONE DEACETYLASE 2; RETINOBLASTOMA-BINDING PROTEIN 4; and RETINOBLASTOMA-BINDING PROTEIN 7 as core components of histone deacetylase complexes. HDAC1 Histone Deacetylase,RPD3L1 Histone Deacetylase,Deacetylase 1, Histone,Deacetylase, HDAC1 Histone,Deacetylase, RPD3L1 Histone,Histone Deacetylase, HDAC1,Histone Deacetylase, RPD3L1
D056572 Histone Deacetylase Inhibitors Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains. HDAC Inhibitor,HDAC Inhibitors,Histone Deacetylase Inhibitor,Deacetylase Inhibitor, Histone,Deacetylase Inhibitors, Histone,Inhibitor, HDAC,Inhibitor, Histone Deacetylase,Inhibitors, HDAC,Inhibitors, Histone Deacetylase

Related Publications

Tooba Abdizadeh, and Mohammad Reza Kalani, and Khalil Abnous, and Zahra Tayarani-Najaran, and Bibi Zahra Khashyarmanesh, and Rahman Abdizadeh, and Razieh Ghodsi, and Farzin Hadizadeh
Design, synthesis and biological evaluation of coumarin-based N-hydroxycinnamamide derivatives as novel histone deacetylase inhibitors with anticancer activities.
August 2020, Bioorganic chemistry,
Tooba Abdizadeh, and Mohammad Reza Kalani, and Khalil Abnous, and Zahra Tayarani-Najaran, and Bibi Zahra Khashyarmanesh, and Rahman Abdizadeh, and Razieh Ghodsi, and Farzin Hadizadeh
Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
April 2019, European journal of medicinal chemistry,
Tooba Abdizadeh, and Mohammad Reza Kalani, and Khalil Abnous, and Zahra Tayarani-Najaran, and Bibi Zahra Khashyarmanesh, and Rahman Abdizadeh, and Razieh Ghodsi, and Farzin Hadizadeh
Synthesis and Biological Evaluation of Novel Thiazolyl-Coumarin Derivatives as Potent Histone Deacetylase Inhibitors with Antifibrotic Activity.
February 2019, Molecules (Basel, Switzerland),
Tooba Abdizadeh, and Mohammad Reza Kalani, and Khalil Abnous, and Zahra Tayarani-Najaran, and Bibi Zahra Khashyarmanesh, and Rahman Abdizadeh, and Razieh Ghodsi, and Farzin Hadizadeh
Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
July 2017, European journal of medicinal chemistry,
Tooba Abdizadeh, and Mohammad Reza Kalani, and Khalil Abnous, and Zahra Tayarani-Najaran, and Bibi Zahra Khashyarmanesh, and Rahman Abdizadeh, and Razieh Ghodsi, and Farzin Hadizadeh
Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.
July 2019, Molecules (Basel, Switzerland),
Tooba Abdizadeh, and Mohammad Reza Kalani, and Khalil Abnous, and Zahra Tayarani-Najaran, and Bibi Zahra Khashyarmanesh, and Rahman Abdizadeh, and Razieh Ghodsi, and Farzin Hadizadeh
Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
July 2019, European journal of medicinal chemistry,
Tooba Abdizadeh, and Mohammad Reza Kalani, and Khalil Abnous, and Zahra Tayarani-Najaran, and Bibi Zahra Khashyarmanesh, and Rahman Abdizadeh, and Razieh Ghodsi, and Farzin Hadizadeh
Design, synthesis and biological evaluation of isoquinoline-based derivatives as novel histone deacetylase inhibitors.
September 2015, Bioorganic & medicinal chemistry,
Tooba Abdizadeh, and Mohammad Reza Kalani, and Khalil Abnous, and Zahra Tayarani-Najaran, and Bibi Zahra Khashyarmanesh, and Rahman Abdizadeh, and Razieh Ghodsi, and Farzin Hadizadeh
Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
January 2018, European journal of medicinal chemistry,
Tooba Abdizadeh, and Mohammad Reza Kalani, and Khalil Abnous, and Zahra Tayarani-Najaran, and Bibi Zahra Khashyarmanesh, and Rahman Abdizadeh, and Razieh Ghodsi, and Farzin Hadizadeh
Design, Synthesis and Biological Evaluation of a Novel Series of Thiadiazole- Based Anticancer Agents as Potent Angiogenesis Inhibitors.
January 2021, Anti-cancer agents in medicinal chemistry,
Tooba Abdizadeh, and Mohammad Reza Kalani, and Khalil Abnous, and Zahra Tayarani-Najaran, and Bibi Zahra Khashyarmanesh, and Rahman Abdizadeh, and Razieh Ghodsi, and Farzin Hadizadeh
Novel 4-Oxoquinazoline-Based N-Hydroxypropenamides as Histone Deacetylase Inhibitors: Design, Synthesis, and Biological Evaluation.
February 2021, ACS omega,
Copied contents to your clipboard!